Company

Before a medical technology product becomes available on the open market, it must undergo many laborious technological development steps, and extensive testing and validation procedures. These include both animal studies and studies on sick people.

Precisis conducted the first implantation of its system in 2019 – the ‘first-in-human’ clinical study. Since then, we have developed the perspective of several hundred therapy months and can proudly claim that our initial creative idea has gone on to become a safe and highly effective therapeutic method. The step-by-step, careful and laborious licensing procedure (Medical Device regulation, MDR) is intended primarily to serve patient safety: however, the data evaluation also serves to answer the question whether what may be an expensive innovative therapy should take its place in our health insurance system and be regarded as worthy of reimbursement. We consider ourselves fortunate in that our brain stimulation product is already achieving significant success in people with severe brain disorders.

We take pride in the fact that our product is already presenting a promising alternative for individuals with severe epilepsy conditions. Following market approval in September 2022, several successful implantations have been carried out in specialized epilepsy centers in Germany, Austria, and Switzerland.

When making the decision regarding bioelectronic therapy with EASEE®, a team of specialists and experts is always being consulted. Consequently, we are expanding our in-house team to include a diverse range of professionals. This includes the addition of Field Clinical Engineers, who assist with the system implantation in the operating room. We are also deploying reimbursement specialists to meet the various international requirements. Additionally, we are creating more capacity in the service and communication sectors. Finally, we aim to gather and effectively implement the desires and expectations of patients and their families, and to achieve this, we are currently expanding our social media activities.

Overall, the commercial team, led by CCO Pedro Marques, is undergoing strategic expansion.

In 2021, Precisis and the Australian firm Cochlear Ltd concluded a partnership agreement. The new relationship with Cochlear offers financial benefits for Precisis along with access to Cochlear’s scientific expertise.Cochlear is the world’s leading provider of implantable solutions for people who are hearing- impaired. The firm employs over 4,000 people worldwide and invests more than AUD 180 million annually in research and development. Its products include hearing systems for cochlear implants, bone conduction implants and acoustic implants, which were developed for the treatment of moderate to severe hearing loss. Since 1981, the company has manufactured more than 650,000 implantable devices, which are helping people of all ages to hear in around 180 countries.